About STAAR Surgical (NASDAQ:STAA)
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$82.43 million
Price / Sales7.99
Price / CashN/A
Book Value$0.93 per share
Price / Book17.20
Return on Equity-3.34%
Return on Assets-1.93%
STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions
What is STAAR Surgical's stock symbol?
STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."
How were STAAR Surgical's earnings last quarter?
STAAR Surgical Company (NASDAQ:STAA) issued its quarterly earnings results on Thursday, November, 3rd. The medical instruments supplier reported ($0.02) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.02. The medical instruments supplier earned $20.05 million during the quarter, compared to the consensus estimate of $20.70 million. STAAR Surgical had a negative return on equity of 3.34% and a negative net margin of 2.47%. The firm's revenue for the quarter was up 6.9% compared to the same quarter last year. View STAAR Surgical's Earnings History.
When will STAAR Surgical make its next earnings announcement?
Where is STAAR Surgical's stock going? Where will STAAR Surgical's stock price be in 2017?
2 analysts have issued 12-month price targets for STAAR Surgical's stock. Their forecasts range from $20.00 to $21.00. On average, they expect STAAR Surgical's stock price to reach $20.50 in the next year. View Analyst Ratings for STAAR Surgical.
Who are some of STAAR Surgical's key competitors?
Some companies that are related to STAAR Surgical include MiMedx Group (MDXG), OraSure Technologies (OSUR), Given Imaging (GIVN), Orthofix International (OFIX), Intersect ENT (XENT), Cardiovascular Systems (CSII), K2M Group (KTWO), Exactech (EXAC), Landauer (LDR), Cryolife (CRY), AtriCure (ATRC), Meridian Bioscience (VIVO), Invacare (IVC), Consort Medical (CSRT), Transenterix (TRXC), Surmodics (SRDX), Syneron Medical (ELOS) and Utah Medical Products (UTMD).
Who are STAAR Surgical's key executives?
STAAR Surgical's management team includes the folowing people:
- Caren L. Mason, President, Chief Executive Officer, Director (Age 63)
- Deborah J. Andrews, Chief Financial Officer, Vice President (Age 59)
- Hans-Martin Blickensdoerfer, Senior Vice President - Commercial Operations for Europe, Middle East, Africa, Latin America and China. (Age 52)
- James E. Francese, Senior Vice President of North American and APAC (Age 51)
- Keith Holliday Ph.D., Chief Technology Officer, Vice President (Age 54)
- Surindra Mann, Vice President - Global Financial Planning and Analysis
- William Walter Goodmen, Vice President - Global Human Resources (Age 60)
- Jon K. Hayashida, Vice President - Global Clinical and Medical Affairs
- Philippe Subrin, Vice President-ICL Manufacturing (Age 51)
- Samuel J. Gesten, Vice President - Business Development, Chief Legal Officer and Secretary (Age 55)
Who owns STAAR Surgical stock?
STAAR Surgical's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (1.70%), Cortina Asset Management LLC (1.21%), Rice Hall James & Associates LLC (0.40%), California State Teachers Retirement System (0.16%), Wells Fargo & Company MN (0.16%) and Quantum Capital Management (0.14%). Company insiders that own STAAR Surgical stock include Broadwood Partners Lp, Hans-Martin Blickensdoerfer, Keith Holliday and Richard A Meier. View Institutional Ownership Trends for STAAR Surgical.
Who sold STAAR Surgical stock? Who is selling STAAR Surgical stock?
STAAR Surgical's stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Campbell & CO Investment Adviser LLC, Susquehanna International Group LLP and California State Teachers Retirement System. View Insider Buying and Selling for STAAR Surgical.
Who bought STAAR Surgical stock? Who is buying STAAR Surgical stock?
STAAR Surgical's stock was bought by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Quantum Capital Management, Baillie Gifford & Co., Raymond James Financial Services Advisors Inc., Citadel Advisors LLC, Wells Fargo & Company MN, Prudential Financial Inc. and Trexquant Investment LP. View Insider Buying and Selling for STAAR Surgical.
How do I buy STAAR Surgical stock?
Shares of STAAR Surgical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is STAAR Surgical's stock price today?
One share of STAAR Surgical stock can currently be purchased for approximately $16.00.
How big of a company is STAAR Surgical?
STAAR Surgical has a market capitalization of $664.80 million and generates $82.43 million in revenue each year. The medical instruments supplier earns $-12,120,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. STAAR Surgical employs 336 workers across the globe.
How can I contact STAAR Surgical?
STAAR Surgical's mailing address is 1911 WALKER AVE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]
MarketBeat Community Rating for STAAR Surgical (STAA)MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
STAAR Surgical (NASDAQ:STAA) Earnings History and Estimates Chart
STAAR Surgical (NASDAQ STAA) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||($0.05)||($0.01)||$22.15 million||$21.90 million||View||Listen|
|5/3/2017||Q1 2017||($0.05)||($0.05)||$20.35 million||View||Listen|
|3/2/2017||Q4 2016||($0.02)||$0.02||$22.25 million||$22.10 million||View||Listen|
|11/3/2016||Q316||($0.04)||($0.02)||$20.70 million||$20.05 million||View||Listen|
|8/3/2016||Q216||($0.05)||($0.05)||$19.88 million||$21.00 million||View||Listen|
|5/11/2016||Q116||($0.17)||($0.01)||$19.60 million||$19.30 million||View||Listen|
|3/2/2016||Q415||($0.02)||$0.01||$19.11 million||$20.90 million||View||Listen|
|10/28/2015||Q315||($0.04)||($0.04)||$17.87 million||$18.80 million||View||Listen|
|4/29/2015||Q115||($0.04)||$0.03||$17.85 million||$18.90 million||View||Listen|
|2/25/2015||Q414||($0.05)||($0.03)||$16.60 million||$16.60 million||View||Listen|
|10/30/2014||Q314||$0.02||($0.04)||$19.53 million||$18.20 million||View||Listen|
|7/30/2014||Q214||$0.03||$0.01||$19.80 million||$20.05 million||View||Listen|
|4/28/2014||Q114||$0.01||$0.04||$19.44 million||$20.20 million||View||Listen|
|2/26/2014||Q413||$0.02||$0.02||$18.98 million||$18.90 million||View||Listen|
|10/30/2013||Q313||$0.02||$0.04||$17.35 million||$17.10 million||View||Listen|
|7/31/2013||Q2 2013||$0.04||$0.05||$17.40 million||$18.20 million||View||Listen|
|5/1/2013||Q1 2013||$0.04||$0.08||$17.27 million||$18.00 million||View||Listen|
|2/27/2013||Q4 2012||$0.03||$0.01||$17.55 million||$16.50 million||View||Listen|
|10/31/2012||Q312||$0.01||$0.04||$16.78 million||$15.90 million||View||N/A|
STAAR Surgical (NASDAQ:STAA) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.19 EPS
Dividend History for STAAR Surgical (NASDAQ:STAA)
No dividend announcements for this company have been tracked by MarketBeat.com
STAAR Surgical (NASDAQ STAA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 77.73%
STAAR Surgical (NASDAQ STAA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/21/2017||Keith Holliday||VP||Sell||6,000||$16.65||$99,900.00|| |
|12/9/2016||Hans-Martin Blickensdoerfer||VP||Sell||25,000||$11.14||$278,500.00|| |
|6/29/2016||Broadwood Partners Lp||Major Shareholder||Buy||14,144||$5.24||$74,114.56|| |
|5/25/2016||Broadwood Partners Lp||Major Shareholder||Buy||77,842||$5.16||$401,664.72|| |
|5/24/2016||Broadwood Partners Lp||Major Shareholder||Buy||70,000||$5.16||$361,200.00|| |
|5/23/2016||Broadwood Partners Lp||Major Shareholder||Buy||3,138||$5.24||$16,443.12|| |
|5/20/2016||Richard A Meier||Director||Sell||25,000||$5.35||$133,750.00|| |
|5/17/2016||Broadwood Partners Lp||Major Shareholder||Buy||9,313||$5.23||$48,706.99|| |
|5/16/2016||Broadwood Partners Lp||Major Shareholder||Buy||336,210||$5.49||$1,845,792.90|| |
|2/9/2016||Broadwood Partners Lp||Major Shareholder||Buy||91,770||$6.25||$573,562.50|| |
|2/3/2016||Broadwood Partners Lp||Major Shareholder||Buy||121,599||$6.40||$778,233.60|| |
|2/1/2016||Broadwood Partners Lp||Major Shareholder||Buy||65,983||$6.48||$427,569.84|| |
|1/27/2016||Broadwood Partners Lp||Major Shareholder||Buy||239,013||$6.63||$1,584,656.19|| |
|1/26/2016||Broadwood Partners Lp||Major Shareholder||Buy||112,900||$6.60||$745,140.00|| |
|1/25/2016||Broadwood Partners Lp||Major Shareholder||Buy||81,752||$6.74||$551,008.48|| |
|1/20/2016||Broadwood Partners Lp||Major Shareholder||Buy||72,858||$6.75||$491,791.50|| |
|1/15/2016||Broadwood Partners Lp||Major Shareholder||Buy||135,725||$6.73||$913,429.25|| |
|1/11/2016||Broadwood Partners Lp||Major Shareholder||Buy||86,586||$6.83||$591,382.38|| |
|1/7/2016||Broadwood Partners Lp||Major Shareholder||Buy||267,047||$6.95||$1,855,976.65|| |
|1/4/2016||Broadwood Partners Lp||Major Shareholder||Buy||165,461||$7.11||$1,176,427.71|| |
|9/29/2015||Broadwood Partners Lp||Major Shareholder||Buy||311,099||$7.08||$2,202,580.92|| |
|8/25/2015||Broadwood Partners Lp||Major Shareholder||Buy||188,881||$7.17||$1,354,276.77|| |
|8/24/2015||Caren L Mason||CEO||Buy||10,000||$7.34||$73,400.00|| |
|4/6/2015||Samuel J Gesten||VP||Sell||3,223||$7.14||$23,012.22|| |
|3/3/2015||Robin Hughes||VP||Sell||23,253||$15.82||$367,862.46|| |
|11/19/2014||Broadwood Partners Lp||Major Shareholder||Buy||189,646||$8.64||$1,638,541.44|| |
|11/18/2014||Broadwood Partners Lp||Major Shareholder||Buy||39,400||$8.67||$341,598.00|| |
|11/17/2014||Broadwood Partners Lp||Major Shareholder||Buy||118,200||$8.63||$1,020,066.00|| |
|11/10/2014||Broadwood Partners Lp||Major Shareholder||Buy||500||$8.79||$4,395.00|| |
|11/7/2014||Broadwood Partners Lp||Major Shareholder||Buy||80,000||$8.92||$713,600.00|| |
|11/4/2014||Broadwood Partners Lp||Major Shareholder||Buy||260,341||$9.20||$2,395,137.20|| |
|5/15/2014||John Moore||Director||Sell||2,800||$14.87||$41,636.00|| |
|3/19/2014||James Francese||VP||Sell||16,666||$17.22||$286,988.52|| |
|3/17/2014||Robin Hughes||VP||Sell||5,672||$16.61||$94,211.92|| |
|9/4/2013||Deborah Andrews||CFO||Sell||50,000||$12.88||$644,000.00|| |
|8/20/2013||Deborah Andrews||CFO||Sell||33,515||$11.65||$390,449.75|| |
|8/12/2013||Deborah Andrews||CFO||Sell||9,079||$11.62||$105,497.98|| |
|8/7/2013||Deborah Andrews||CFO||Sell||11,721||$11.79||$138,190.59|| |
|5/9/2013||Deborah J Andrews||CFO||Sell||5,000||$8.96||$44,800.00|| |
|12/11/2012||John C Moore||Director||Buy||5,000||$5.46||$27,300.00|| |
|11/15/2012||Broadwood Partners Lp||Major Shareholder||Buy||2,618||$5.00||$13,090.00|| |
|11/15/2012||Mark B Logan||Director||Buy||3,600||$5.22||$18,792.00|| |
|11/14/2012||Barry G Caldwell||CEO||Buy||5,000||$5.04||$25,200.00|| |
|11/2/2012||Broadwood Partners Lp||Major Shareholder||Buy||22,572||$5.00||$112,860.00|| |
|8/9/2012||Barry G Caldwell||CEO||Buy||5,000||$6.57||$32,850.00|| |
STAAR Surgical (NASDAQ STAA) News Headlines
STAAR Surgical (NASDAQ:STAA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
STAAR Surgical (NASDAQ:STAA) Income Statement, Balance Sheet and Cash Flow Statement
STAAR Surgical (NASDAQ STAA) Stock Chart for Wednesday, December, 13, 2017